Overview

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).

Phase:

Phase 2

Details

Lead Sponsor:

Regeneron Pharmaceuticals

Collaborator:

Sanofi